Ads
related to: dupixent commercial- Coverage Support
Learn More About Insurance
Download Sample Letter
- Resources
Get Help With Access
Download Resources Today
- Coverage Support
Search results
Regeneron, Sanofi to seek new Dupixent approval in US after COPD success
BioPharma Dive via Yahoo Finance· 6 months agoResults from the second of two Phase 3 trials testing the blockbuster drug in the respiratory...
What This Drug News Could Mean for Sanofi Shareholders
Motley Fool· 1 year agoIn the middle of December, Sanofi's (NASDAQ: SNY) and Regeneron Pharmaceuticals' (NASDAQ: REGN)...
Regeneron Pharmaceuticals Inc (REGN) Reports Modest Revenue Growth Amidst Strong Dupixent Sales
GuruFocus.com via Yahoo Finance· 4 months agoRevenue Growth: Full year 2023 revenues increased by 8% to $13.12 billion, with a 14% rise excluding...
Sanofi Expects Moderate 2023 Profit Growth On Dupixent Demand, But Dampened By Aubagio Generics...
Benzinga via Yahoo Finance· 1 year agoSanofi SA (NASDAQ: SNY) forecasts 2023 adjusted earnings per share to grow by a "low single-digit"...
Sanofi (SNY) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 1 month agoImage source: The Motley Fool. Sanofi (NASDAQ: SNY) Q1 2024 Earnings Call Apr 25, 2024, 8:30 a.m. ET Contents: Prepared Remarks Questions and Answers...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q4 2022 Earnings Call Transcript (Corrected)
Insider Monkey via Yahoo Finance· 1 year agoRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q4 2022 Earnings Call Transcript February 3, 2023...
Regeneron Pharmaceuticals Inc (REGN) Reports 15% Revenue Growth in Q3 2023
GuruFocus.com via Yahoo Finance· 7 months agoRegeneron Pharmaceuticals Inc (NASDAQ:REGN) reported a 15% increase in revenues to $3.36 billion in...
Analysis-Meagre medicine cabinet leaves Sanofi unloved
Reuters via Yahoo Finance· 2 years agoSanofi's recent stock rout underscores the pressure on the French drug maker to redouble its efforts...
Sanofi trial failure halts work on breast cancer treatment amcenestrant
Reuters via Yahoo News· 2 years agoSanofi has stopped further work on amcenestrant, a treatment once seen to have strong commercial...
Regeneron Pharmaceuticals Inc (REGN) Q1 2024 Earnings Call Transcript Highlights: Key Financial ...
GuruFocus.com via Yahoo Finance· 4 weeks agoRevenue: Grew 7% year-over-year to $3.1 billion, excluding COVID antibodies contributions. Net Income: First quarter diluted net income per share was $9.55. Free Cash Flow: Generated $1.4 billion ...
Ads
related to: dupixent commercial